A reason why the ERBB2 gene is amplified and not mutated in breast cancer

Alterations of receptor-type tyrosine kinases (RTK) are frequent in human cancers. They can result from translocation, mutation or amplification. The ERBB2 RTK is encoded by a gene that is amplified in about 20% breast cancers. The question is: why is this RTK specifically subjected to this type of alteration? We propose that ERBB2 gene amplification is used to overcome repression of its expression by sequence-specific transcription factors.

• Publication year

  2009

• Venue

  Cancer Cell International

• Publication date

  2009-02-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/1475-2867-9-5PMID 19226453PMCID 2649042
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene.

  2021influential reference
• How different are luminal A and basal breast cancers?

  2009cited by this paper
• A Negative Feedback Regulatory Loop Associates the Tyrosine Kinase Receptor ERBB2 and the Transcription Factor GATA4 in Breast Cancer Cells

  2009cited by this paper
• Identification of ALK as a major familial neuroblastoma predisposition gene

  2008cited by this paper
• Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

  2008cited by this paper
• Oncogenic mutations of ALK kinase in neuroblastoma

  2008cited by this paper
• Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen

  2008cited by this paper
• Proliferation of breast cancer cells: regulation, mediators, targets for therapy.

  2008cited by this paper
• HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion

  2008cited by this paper
• Activating mutations in ALK provide a therapeutic target in neuroblastoma

  2008cited by this paper
• FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene.

  2007cited by this paper
• The emerging roles of forkhead box (Fox) proteins in cancer

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Integrated profiling of basal and luminal breast cancers.

  2007cited by this paper
• Modulation of gene transcription by natural products--a viable anticancer strategy.

  2007cited by this paper
• CtIP, a candidate tumor susceptibility gene is a team player with luminaries.

  2006cited by this paper
• Linkage between EGFR family receptors and nuclear factor kappaB (NF‐κB) signaling in breast cancer

  2006cited by this paper
• Identification and validation of an ERBB2 gene expression signature in breast cancers

  2004cited by this paper
• Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment

  2001cited by this paper
• Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.

  2001cited by this paper
• Targeting HER2: recent developments and future directions for breast cancer patients.

  2001cited by this paper
• Ets regulation of the erbB2 promoter

  2000cited by this paper
• The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis

  2000cited by this paper
• Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor

  2000cited by this paper
• c-Myb Repression of c- erbB-2 Transcription by Direct Binding to the c- erbB-2 Promoter (*)

  1995cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Elevated expression of wildtype RhoC promotes ErbB2- and Pik3ca-induced mammary tumor formation

  2024cites this paper
• HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer

  2022cites this paper
• A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast Cancer

  2022influential citation
• Functional Common and Rare ERBB2 Germline Variants Cooperate in Familial and Sporadic Cancer Susceptibility

  2021cites this paper
• Differential effects of cisplatin on cybrid cells with varying mitochondrial DNA haplogroups

  2020cites this paper
• ERBB2b mRNA isoform encodes a nuclear variant of the ERBB2 oncogene in breast cancer

  2020cites this paper
• Mitochondrial DNA copy number instability in ERBB2-amplified breast cancer tumors

  2018cites this paper
• Identification of markers to predict benefit from trastuzumab treatment

  2017cites this paper
• Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines

  2014cites this paper
• Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer

  2013cites this paper
• Inhibiting Tumor Protein D52 function for anti-cancer therapy application

  2013cites this paper
• Signaling pathway switch in breast cancer

  2013cites this paper
• Autophagy in breast cancer and its implications for therapy.

  2013cites this paper
• HER2-overexpressing breast cancer: time for the cure with less chemotherapy?

  2011cites this paper
• In silico sequence specific analysis of ERBB2 RTK alterations responsible for neuroectodermal tumors of Homo sapiens

  2010cites this paper
• Early response to ErbB2 over‐expression in polarized Caco‐2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling

  2010cites this paper
• The Role of Myeloid-Derived Suppressor Cells in the Immunotherapy of Breast Carcinomas

  2009cites this paper